Upadacitinib Meets Primary End Point of Phase 2 Trial for Vitiligo and Advances to Phase 3
20 October 2023
Upadacitinib Meets Primary End Point of Phase 2 Trial for Vitiligo and Advances to Phase 3
AbbVie recently announced that its phase 2b study investigating upadacitinib (Rinvoq)…
